Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04644003 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetics Study of STP1 in a Subgroup of Patients With Autism Spectrum Disorder (ASD)
A Phase 1 study, sponsored by Stalicla.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04644003 is a Phase 1 study that has completed, run by Stalicla. The registered enrollment target is 12 participants.
The verdict
NCT04644003, a Phase 1 study, has completed, sponsored by Stalicla.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate safety and tolerability in a subgroup of patients with Autism Spectrum Disorder (ASD). In addition, Pharmacokinetics and Pharmacodynamics, as well as efficacy of STP1 are being explored.
Interventions
- DRUG Placebo
- DRUG STP1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-12-07 |
| Est. Completion | 2022-01-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04644003
The ClinicalTrials.gov registry entry for NCT04644003 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stalicla, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04644003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04644003 about?
NCT04644003 is a clinical study titled "Safety, Tolerability and Pharmacokinetics Study of STP1 in a Subgroup of Patients With Autism Spectrum Disorder (ASD)". The main purpose of this study is to evaluate safety and tolerability in a subgroup of patients with Autism Spectrum Disorder (ASD). In addition, Pharmacokinetics and Pharmacodynamics, as well as efficacy of STP1 are being explored.
What is the current status of trial NCT04644003?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2020-12-07. Estimated completion is 2022-01-28.
What interventions are being tested in trial NCT04644003?
The interventions under investigation include: Placebo (DRUG), STP1 (DRUG).
Who is sponsoring clinical trial NCT04644003?
This trial is sponsored by Stalicla, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.